福安药业(300194) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 reached ¥654.47 million, an increase of 3.33% year-on-year, while the total revenue for the year-to-date period was ¥1.98 billion, reflecting an 11.17% growth compared to the same period last year[7]. - Net profit attributable to shareholders for Q3 2023 was ¥90.95 million, representing an 88.64% increase year-on-year, and the year-to-date net profit reached ¥251.84 million, up 85.13% from the previous year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥81.49 million, a 105.20% increase year-on-year, with a year-to-date figure of ¥224.46 million, up 95.53%[7]. - Total operating revenue for the current period reached ¥1,982,986,710.24, an increase of 11.16% compared to ¥1,783,740,797.09 in the previous period[28]. - Net profit for the current period was ¥254,779,914.23, significantly higher than ¥133,714,580.12 from the previous period, marking an increase of 90.55%[29]. - Earnings per share (EPS) for the current period was ¥0.21, compared to ¥0.11 in the previous period, indicating a 90.91% increase[30]. - Total comprehensive income for the current period was ¥266,144,435.94, compared to ¥163,709,563.32 in the previous period, reflecting an increase of 62.73%[30]. Assets and Liabilities - The company's total assets as of the end of Q3 2023 were ¥6.17 billion, a 4.89% increase from the end of the previous year, while total equity attributable to shareholders was ¥4.15 billion, up 5.19%[7]. - Total current assets amount to 2,108,699,190.49 RMB, an increase from 1,927,072,477.67 RMB[26]. - Total non-current assets are 4,056,738,176.96 RMB, up from 3,950,907,896.75 RMB[26]. - Total liabilities increased to ¥2,011,396,388.63 from ¥1,931,511,616.76, representing a growth of 4.88%[27]. - Total equity rose to ¥4,154,040,978.82, up from ¥3,946,468,757.66, reflecting an increase of 5.26%[27]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥167.85 million, a decrease of 38.37% compared to the same period last year[18]. - Operating cash flow for the current period is ¥167,853,721.28, a decrease of 38.3% compared to ¥272,363,777.43 in the previous period[31]. - Cash outflow from operating activities increased to ¥1,782,407,960.83 from ¥1,682,764,100.87, resulting in a net cash flow from operating activities of ¥167,853,721.28[31]. - Cash inflow from financing activities increased to ¥832,702,540.58 from ¥549,668,926.69, with net cash flow from financing activities at ¥145,167,086.20[32]. - The total cash and cash equivalents at the end of the period is ¥825,097,299.65, up from ¥730,906,667.80 in the previous period[32]. Investment and R&D - The company reported a significant increase in investment income of ¥56.76 million, up 60.78% year-on-year, primarily due to increased profits from its associate, Fumin Bank[16]. - Research and development expenses for the current period were ¥98,871,009.50, compared to ¥85,808,880.34 in the previous period, showing an increase of 15.19%[29]. - The company’s research and development efforts have begun to yield results, with several products passing consistency evaluations and obtaining production licenses, contributing to increased sales revenue[11]. - Investment income from joint ventures and associates was ¥56,695,150.26, compared to ¥35,260,691.75 in the previous period, indicating a growth of 60.93%[29]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 46,454[20]. - The largest shareholder, Wang Tianxiang, holds 24.00% of shares, totaling 285,499,420 shares[20]. Other Information - The company experienced a 30.34% increase in tax and additional charges, totaling ¥19.72 million, attributed to higher revenue leading to increased VAT-related charges[14]. - The company has not disclosed any new strategies or future outlook in the provided documents[23]. - The company has not yet audited the third quarter report for 2023[33].